Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The Development and Maintenance of Paclitaxel-Induced Neuropathic Pain Requires Activation of the Sphingosine 1-Phosphate Receptor Subtype 1.
Neurocardiogenic Pulmonary Oedema: Initial Presentation of Multiple Sclerosis.
The Sphingosine 1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Post-Infarction Left Ventricular Remodeling in a Porcine Model of Ischemia-Reperfusion.
[A Patient with Acute Limbic Encephalitis Associated with Anti-Glutamate Receptor Antibodies and Subsequent Optic Neuritis].
Treatment of Neuropathic Pain and Functional Limitations Associated With Multiple Sclerosis Using an MRI-Compatible Spinal Cord Stimulator: A Case Report With Two Year Follow-Up and Literature Review.
Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity.
The Role of CD8+ T Cells and Their Local Interaction with CD4+ T Cells in Myelin Oligodendrocyte Glycoprotein35-55-Induced Experimental Autoimmune Encephalomyelitis.
Effect of IL-17A blockade with secukinumab in autoimmune diseases.
The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
A case of septal panniculitis secondary to interferon treatment.
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Impact of multiple sclerosis relapses on progression diminishes with time.
FTY720 Impairs Mucosal Immunity and Clearance of the Enteric Pathogen Citrobacter rodentium.
Limb ataxia originating from peri-central sulcus demyelinating lesion in multiple sclerosis.
Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
Managing MS: Trends, Issues, and Perspectives.
Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica.
Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience.
Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.
Increased resistin levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica.
Imaging new lesions: Enhancing our understanding of multiple sclerosis pathogenesis.
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Effects of Imatinib Mesylate in Mouse Models of Multiple Sclerosis and In vitro Determinants.
Enhanced In Vivo Efficacy of a Type I Interferon Superagonist with Extended Plasma Half-life in a Mouse Model of Multiple Sclerosis.

Pages